Rivastigmine interferes with the pharmacological activity of hydromethylthionine on presynaptic proteins in the line 66 model of frontotemporal dementia
Schwab, K., Strachan, L., Anschuetz, A., Dreesen, E. S., Magbagbeolu, M., Melis, V., Theuring, F., Harrington, C., Wischik, C., Riedel, G.
High-affinity antibodies specific to the core region of the tau protein exhibit diagnostic and therapeutic potential for Alzheimer’s disease
Arastoo, M., Penny, L. K., Lofthouse, R. A., Abdallah, A., Abrahamsson, A., Marini, P., Melis, V., Riedel, G., Harrington, C., Wischik, C., Porter, A., Palliyil, S.
Rescue of synaptosomal glutamate release defects in tau transgenic mice by the tau aggregation inhibitor hydromethylthionine
Cranston, A., Kraev, I., Stewart, M. G., Horsley, D., Robinson, L., Dreesen, E. S., Armstrong, P., Palliyil, S., Harrington, C., Wischik, C., Riedel, G.
LETC inhibits α-Syn aggregation and ameliorates motor deficiencies in the L62 mouse model of synucleinopathy
Schwab, K., Frahm, S., Magbagbeolu, M., Horsley, D., Goatman, E., Melis, V., Theuring, F., Ishaq, A., Storey, J. M. D., Harrington, C., Wischik, C., Riedel, G.
European Journal of Pharmacology, vol. 970, 176505